# US 2023/0066474 A1 · Lysosome-targeting antibody-drug conjugate and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0066474 A1
- Document ID: US20230066474A1
- Status: Published application
- Kind: A1
- Application number: 17/765,785
- Filed: 2020-10-09
- Published: 2023-03-02
- Earliest claimed: 2019-10-09
- Assignees: Sun Yat-Sen University
- Applicants: Sun Yat-Sen University
- Inventors: Xiaoqing CAI; Xianxing JIANG
- Web page: https://patentgrep.com/patent/US20230066474A1

## CPC

- A61K 31/215: of carboxylic acids
- A61K 31/10: Sulfides; Sulfoxides; Sulfones
- A61K 31/4192: 1,2,3-Triazoles
- A61K 31/5375: 1,4-Oxazines, e.g. morpholine
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 47/645: {Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT}
- A61K 47/68031: {the drug being an auristatin}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61P 35/00: Antineoplastic agents
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 16/32: against translation products of oncogenes
- A61K 2039/505: {comprising antibodies}
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/77: Internalization into the cell
- Y02P 20/55: Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

Disclosed in the present invention is a lysosome-targeting antibody-drug conjugate and use thereof. The structure of the antibody-drug conjugate is Drn1AbOn2; wherein, Dr is a drug, Ab is an antibody, and O is a lysosome-targeting small molecule or a functional peptide for increasing the lysosomal targeting ability of the antibody-drug conjugate; n1 and n2 are integers greater than or equal to 1, and n1 and n2 are identical or different.

## Claims

### Claim 1

A lysosome-targeting antibody-drug conjugate, wherein the structure of the antibody-drug conjugate is as follows:
Drn1AbOn2;
wherein, Dr is a drug;
Ab is an antibody;
O is a lysosome-targeting small molecule or a functional peptide for increasing the lysosome-targeting ability of the antibody-drug conjugate;
n1 and n2 are integers greater than or equal to 1, and n1 and n2 are identical or different.

### Claim 2 (depends on 1)

The lysosome-targeting antibody-drug conjugate according to claim 1, wherein the antibody is a monoclonal antibody or a nanobody, and the monoclonal antibody is one selected from Glembatumumab, Vandortuzumab, Tisotumab, Enfortumab, Cetuximab, Coltuximab, Lorvotuzumab, Gemtuzumab, Trastuzumab, and Ladiratuzumab; the nanobody is one selected from 7D12, EGA1, 9G8, C7b, 5F7, and 2Rs15d.

### Claim 3 (depends on 1)

The lysosome-targeting antibody-drug conjugate according to claim 1, wherein the functional peptide is a lysosome-sorting peptide, a cell-penetrating peptide or a composition of the lysosome-sorting peptide and the cell-penetrating peptide; the functional peptide is conjugated to the C-terminal of the antibody.

### Claim 4 (depends on 3)

The lysosome-targeting antibody-drug conjugate according to claim 3, wherein the lysosome-sorting peptide is one selected from NPXY, YXXØ, [DE]XXXL[LI], DXXLL, NPFXD, NPFXXD, wherein the X is any amino acid, the Ø is any amino acid with a bulky hydrophobic side chain, the N is asparagine, the P is proline, the Y is tyrosine, the E is glutamic acid, the L is leucine, the I is isoleucine, the F is phenylalanine, and the D is aspartic acid, the [DE] is represented as one of the D or the E, and the [LI] is represented as one of the L or the I.

### Claim 5 (depends on 3)

The lysosome-targeting antibody-drug conjugate according to claim 3, wherein the cell-penetrating peptide is one selected from a cationic cell-penetrating peptide, an amphiphilic cell-penetrating peptide, and a hydrophobic cell-penetrating peptide.

### Claim 6 (depends on 5)

The lysosome-targeting antibody-drug conjugate according to claim 5, wherein the cationic penetrating peptide is one selected from polyarginine, HIV-TAT, DPV1047, and Penetratin; the amphiphilic penetrating peptide is one selected from MPG, PVEC, MAP, Pept-1, Transportan, and P28; the hydrophobic penetrating peptide is one selected from C105Y, PFVYLI, and Pep-1.

### Claim 7 (depends on 1)

The lysosome-targeting antibody-drug conjugate according to claim 1, wherein the lysosome-targeting small molecule is conjugated to a side chain of an amino acid of the antibody.

### Claim 8 (depends on 7)

The lysosome-targeting antibody-drug conjugate according to claim 7, wherein the side chain of the amino acid is a side chain of a natural amino acid or a bioorthogonal group.

### Claim 9 (depends on 8)

The lysosome-targeting antibody-drug conjugate according to claim 8, wherein the side chain of the natural amino acid is one selected from a side chain of lysine and a side chain of cysteine; the bioorthogonal group is one selected from an azide group, an alkynyl group, an aldehyde group, a ketone group, and a fluorosulfate group.

### Claim 10 (depends on 1)

The lysosome-targeting antibody-drug conjugate according to claim 1, wherein the lysosome-targeting small molecule is a pH-sensitive group-containing compound or a sugar-group containing compound.

### Claim 11 (depends on 10)

The lysosome-targeting antibody-drug conjugate according to claim 10, wherein the pH-sensitive group is one selected from sulfonic acid group, 4-morpholinyl group, 2-(2-morpholinoethylamino)ethyl group, and polyethylene glycol group.

### Claim 12 (depends on 10)

The lysosome-targeting antibody-drug conjugate according to claim 10, wherein the sugar-group is one selected from glucose, mannose, mannose-6-phosphate, and galactose.

### Claim 13

A method for cancer treatment, the method comprising:
a lysosome-targeting antibody-drug conjugate, wherein the structure of the antibody-drug conjugate is as follows:
Drn1AbOn2;
wherein, Dr is a drug;
Ab is an antibody;
O is a lysosome-targeting small molecule or a functional peptide for increasing the lysosome-targeting ability of the antibody-drug conjugate;
n1 and n2 are integers greater than or equal to 1, and n1 and n2 are identical or different.
